Allogene Therapeutics Inc (ALLO)

Jul 06, 2026

Form 4 Allogene Therapeutics Inc For: 6 July By Investing.com - Investing.com Canada

Jul 06, 2026

Jul 06, 2026

Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs - Stock Titan

Jul 06, 2026

Jul 05, 2026

ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits

Jul 05, 2026

Jul 04, 2026

Allogene Therapeutics: High-Upside Bet On The Next Wave Of CAR-T Innovation (NASDAQ:ALLO) - Seeking Alpha

Jul 04, 2026

Jul 02, 2026

ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill

Jul 02, 2026

Jun 30, 2026

Allogene at H.C. Wainwright conference: cema-cel data lift strategy By Investing.com - Investing.com Nigeria

Jun 30, 2026

Jun 28, 2026

Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView

Jun 28, 2026

Jun 28, 2026

Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions - Yahoo Finance

Jun 28, 2026

Jun 27, 2026

Price to earnings forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView

Jun 27, 2026

Jun 27, 2026

Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Jun 27, 2026

Enterprise value to revenue forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Jun 27, 2026

Price to book forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Jun 27, 2026

Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView

Jun 27, 2026

Jun 27, 2026

Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Jun 26, 2026

Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO) - TradingView

Jun 26, 2026

Jun 25, 2026

Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN

Jun 25, 2026

Jun 25, 2026

ALLO Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 25, 2026

Allogene Therapeutics unveils strategy to overcome autologous CAR T cell therapy limitations - Traders Union

Jun 25, 2026

Jun 25, 2026

Allogene Therapeutics (ALLO) Short Interest & Short Float | Updated Jun 2026 $ALLO - MarketBeat

Jun 25, 2026

Jun 24, 2026

Recent pharma exec shake-ups signal strategic shifts - Pharma Voice

Jun 24, 2026

Jun 23, 2026

Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria

Jun 23, 2026

Jun 23, 2026

Allogene (ALLO) director Kazam converts 47,700 RSUs and receives 95,400-unit equity grant - Stock Titan

Jun 23, 2026

Jun 23, 2026

Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs - Stock Titan

Jun 23, 2026

Jun 23, 2026

Allogene Therapeutics (ALLO) director receives 144,400 stock options grant - Stock Titan

Jun 23, 2026

Jun 23, 2026

Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award - Stock Titan

Jun 23, 2026

Jun 23, 2026

Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery - Stock Titan

Jun 23, 2026

Jun 23, 2026

[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan

Jun 23, 2026

Jun 23, 2026

Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery - Stock Titan

Jun 23, 2026

Jun 22, 2026

Form 424B5 Allogene Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa

Jun 22, 2026

Jun 22, 2026

Allogene Therapeutics (NASDAQ: ALLO) doubles authorized shares and files $135M ATM plan - Stock Titan

Jun 22, 2026

Jun 22, 2026

Allogene (NASDAQ: ALLO) launches $135M ATM program with TD Cowen at $2.00 ref - Stock Titan

Jun 22, 2026

Jun 19, 2026

Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News

Jun 19, 2026

Jun 18, 2026

ALLO: All proposals, including director elections and share increase, were approved without contest - TradingView

Jun 18, 2026

Jun 18, 2026

ALLO: All proposals passed, including director elections and share authorization increase - TradingView

Jun 18, 2026

Jun 18, 2026

Allogene Therapeutics Inc (ALLO) Institutional Confidence - TradingKey

Jun 18, 2026

Jun 17, 2026

Allogene Therapeutics Inc (ALLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026

Jun 17, 2026

Allogene Therapeutics Inc (ALLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026

Jun 17, 2026

Allogene Therapeutics Inc (ALLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026

Jun 17, 2026

How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease - Insider Monkey

Jun 17, 2026

Jun 16, 2026

Allogene Therapeutics Inc (ALLO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 16, 2026

Jun 16, 2026

Allogene Therapeutics Inc (ALLO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 16, 2026

Jun 16, 2026

Allogene Therapeutics Inc (ALLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 16, 2026

Jun 15, 2026

Allogene Therapeutics Stock Surges on Optimistic Trial Results and Price Target Increase - timothysykes.com

Jun 15, 2026

Jun 12, 2026

Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2026